DoD Kidney Cancer, Translational Research Partnership Award | W81XWH 21 KCRP TRPA

Opportunity Information: Apply for W81XWH 21 KCRP TRPA

The DoD Kidney Cancer Research Program (KCRP) Translational Research Partnership Award (FY21) is designed to speed up the path from promising kidney cancer discoveries to real-world clinical use by funding tightly integrated collaborations between a clinician and a research scientist. The core idea is that certain kidney cancer problems are more likely to be solved when laboratory and clinical perspectives are combined from the start, rather than run as separate projects that only connect later. To fit the intent of the award, the proposal has to be built around a genuine two-way partnership, where both investigators share equal intellectual ownership of the research question, the study design, and the interpretation of results. Multi-institutional teams are encouraged, and the program is open to applicants broadly (no narrow institutional eligibility limits beyond what is stated in the full announcement).

A central requirement is that the partnership includes two independent, faculty-level (or equivalent) investigators serving as co-leads, with one acting as the Initiating PI and the other as the Partnering PI. The Initiating PI handles most submission-related administration, but both PIs are expected to contribute substantially to the full application package, including the project narrative and statement of work. If selected, each PI is expected to be named on an individual award within the recipient organization, reflecting the structure of the partnership rather than a simple subcontract arrangement. At least one member of the team must bring prior experience in kidney cancer research or kidney cancer patient care, but the mechanism also explicitly welcomes experts from outside the kidney cancer field when their expertise could unlock new approaches.

The research itself must be translational in a strong sense, meaning it should push an idea toward clinical application and should be informed by an ongoing exchange between the clinic and the lab. The program emphasizes that translation should not be treated as a one-direction pipeline from bench to bedside; instead, proposals should show a reciprocal flow of ideas and information, where clinical observations shape laboratory work and laboratory findings meaningfully feed back into clinically relevant questions. Projects can be sparked by many types of observations, including laboratory discoveries, population-level analyses, or insights from direct patient care (including clinician observations and anecdotal experience), as long as the resulting work is rigorous and positioned to move the field forward.

Several features are highlighted as essential to competitiveness. First is partnership: the work should clearly depend on the unique skills and contributions of each partner, not simply use the clinician as a source of samples or patient access. A proposal where the clinical PI only provides tissue or recruits patients without deep scientific engagement does not meet the intent. Second is translation: applications should show how clinical information will be leveraged to fill knowledge gaps, validate and extend key findings, and explore potentially transformative results, potentially through correlative studies and/or the development or use of annotated biorepositories. Third is impact: the proposed research should plausibly influence kidney cancer research and/or patient care and accelerate progress in areas such as prevention, diagnosis, detection, prognosis, treatment, or survivorship. Importantly, clinical trials are not allowed under this mechanism, although correlative studies tied to an ongoing or completed clinical trial may be supported if the applicants can document access to the necessary specimens and/or data at the time of submission (with confirmation letters required). Fourth is feasibility: the team must show they can access the specimens, datasets, and other resources needed to execute the plan. Finally, preliminary data are required to justify the hypothesis and approach; these data do not have to come directly from kidney cancer studies, but they must credibly support feasibility and rationale.

Because many partnerships will span institutions, the award also places weight on the practical mechanics of collaboration. Applications must include clear interaction plans describing how the PIs and any participating institutions will communicate, coordinate research activities, share progress and results, and transfer data. For multi-institutional projects specifically, an intellectual property plan is required to anticipate and resolve potential IP and material transfer issues and to reduce institutional barriers that might otherwise slow down cooperation and undermine the collaboration.

Programmatically, the work must be relevant to active-duty Service Members, Veterans, other military beneficiaries, and/or the broader American public, aligning the research with DoD health priorities and the needs of military-connected populations. The announcement also points applicants to recommendations from the congressionally mandated Metastatic Cancer Task Force, encouraging proposals that align with those recommendations when appropriate and within the limits of this funding opportunity. In keeping with that emphasis, collaborations between military or Veteran institutions and non-military institutions are strongly encouraged, reflecting the value of combining unique clinical populations, infrastructure, and expertise across systems.

From a funding and administrative standpoint, awards are made as assistance agreements, meaning they will be structured as either a grant or a cooperative agreement depending on the anticipated level of DoD involvement during performance. If the government does not expect substantial involvement, the mechanism is typically a grant; if substantial involvement is anticipated (such as collaboration or participation in aspects of the work), it is typically a cooperative agreement, and the specifics of that involvement will be spelled out in the award. The anticipated budget is capped at $750,000 in direct costs for the full period of performance. The program expected to allocate about $3.6 million total to fund roughly three awards. Key timeline notes included an application deadline of October 5, 2021, with awards expected to be made no later than September 30, 2022, and FY21 funds projected to remain available for use through September 30, 2027, subject to federal funding rules and final award negotiations.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Kidney Cancer, Translational Research Partnership Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 23, 2021.
• Applicants must submit their applications by Oct 05, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 3 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 KCRP TRPA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: